Ypsomed Holding AG · SIX:YPSN

Ypsomed — FY2016/17 Earnings Presentation

56 slides from Ypsomed's earnings presentation, May 24, 2017

  1. Slide 1: Presentation Financial Figures 2016/17

    Ypsomed Presentation Financial Figures 2016/17 Burgdorf, 24. Mai 2017

  2. Slide 2: Important Notice

    Important Notice The information contained in this document has not been independently verified and no representation or warranty, expressed or implied, is made to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained herei

  3. Slide 3: Agenda

    Agenda 1. Introduction 2. Operative business 3. Finances 4. Outlook 5. Questions and answers 3 | Ypsomed Holding AG | Presentation financial figures 2016/17

  4. Slide 4: Ypsomed significantly outperforms own sales expectations

    Ypsomed significantly outperforms own sales expectations 4 | Ypsomed Holding AG | Presentation financial figures 2016/17

  5. Slide 5: Average growth over 12% with marked acceleration during the past financial year

    Average growth over 12% with marked acceleration during the past financial year 5 | Ypsomed Holding AG | Presentation financial figures 2016/17

  6. Slide 6: EBIT target clearly achieved with average EBIT growth of over 50%

    EBIT target clearly achieved with an average EBIT growth of over 50% in the past three years 6 | Ypsomed Holding AG | Presentation financial figures 2016/17

  7. Slide 7: In summary, we are very satisfied with the financial year 16/17

    In summary, we are very satisfied with the financial year 2016/17  CHF 52.6 million growth in sales to CHF 389.6 million (+15.6%).  EBIT increased year-on-year by over 24.4% to CHF 55.3 million (previous year CHF 44.4 million).  The EBIT margin is now new at 14.2% (previous year: 13.2%).  Earnin

  8. Slide 8: Highlights – Launch of the mylife YpsoPump

    Highlights – Launch of the mylife™ YpsoPump® 8 | Ypsomed Holding AG | Presentation financial figures 2016/17

  9. Slide 9: Highlights – Solothurn Business Award 2017

    Highlights – Honoured with Solothurn Business Award 2017 for future-oriented work models 9 | Ypsomed Holding AG | Presentation financial figures 2016/17

  10. Slide 10: Highlights – Opening of a further major production line in Solothurn

    Highlights – Opening of a further major production line in Solothurn in early 2017 10 | Ypsomed Holding AG | Presentation financial figures 2016/17

  11. Slide 11: Highlights – Planning of the new site in Schwerin progresses

    Highlights – Planning of the new site in Schwerin progresses 11 | Ypsomed Holding AG | Presentation financial figures 2016/17

  12. Slide 12: Agenda

    Agenda 1. Introduction 2. Operative business 3. Finances 4. Outlook 5. Questions and answers 12 | Ypsomed Holding AG | Presentation financial figures 2016/17

  13. Slide 13: Changes in disclosure

    Changes in disclosure  Turnover is declared from a sales perspective.  Operating profits are declared at a Group Level for competitive reasons. 13 | Ypsomed Holding AG | Presentation financial figures 2016/17

  14. Slide 14: Business Segments

    Ypsomed Business Segments 14 | Ypsomed Holding AG | Presentation financial figures 2016/17

  15. Slide 15: Diabetes Care

    Ypsomed Diabetes Care 15 | Ypsomed Holding AG | Presentation financial figures 2016/17

  16. Slide 16: Diabetes Care – Accelerated growth following currency-related stagnation

    Ypsomed Diabetes Care – Accelerated growth following currency-related stagnation 16 | Ypsomed Holding AG | Presentation financial figures 2016/17

  17. Slide 17: Diabetes Care – Average growth around 14% in the past three years

    Ypsomed Diabetes Care – Average growth around 14% in the past three years 17 | Ypsomed Holding AG | Presentation financial figures 2016/17

  18. Slide 18: Diabetes Care – mylife YpsoPump is launched

    Ypsomed Diabetes Care – mylife™ YpsoPump® is launched  mylife™ YpsoPump® is on the market in Germany, the Netherlands, the UK and Czechia.  A further 10 markets will follow by the end of the financial year 2017/18.  Feedback from patients is promising and the patient base is growing as expected.

  19. Slide 19: Diabetes Care – All from a single source with mylife YpsoPump System components

    Ypsomed Diabetes Care – All from a single source with the various mylife™ YpsoPump® System components 19 | Ypsomed Holding AG | Presentation financial figures 2016/17

  20. Slide 20: Diabetes Care – mylife YpsoPump received extremely well by first users

    Ypsomed Diabetes Care – mylife™ YpsoPump® is received extremely well by first users  “Very easy to operate.”  “It’s a child’s play.”  “Does what it has to do.”  “Programming is so easy, size is great, silicone case and clip are handy, infusion sets are comfortable with easy insertion.” 20 | Ypso

  21. Slide 21: mylife YpsoPump further product developments in 2017/18

    Ypsomed Diabetes Care – mylife™ YpsoPump® further product developments in the financial year 2017/18 21 | Ypsomed Holding AG | Presentation financial figures 2016/17

  22. Slide 22: mylife YpsoPump further product developments in 2017/18

    Ypsomed Diabetes Care – mylife™ YpsoPump® further product developments in the financial year 2017/18  Insulin pumps: no more age restrictions (minimal basal rate lowered from 0.05 U/h to 0.02 U/h), permanent Bluetooth connectivity for data exchange with mylife™ App.  App and Software: introduction

  23. Slide 23: Diabetes Care – mylife OmniPod launch in France surpasses expectations

    Ypsomed Diabetes Care – mylife™ OmniPod® launch in France surpasses expectations 23 | Ypsomed Holding AG | Presentation financial figures 2016/17

  24. Slide 24: Negotiations ongoing for distribution of mylife OmniPod after June 2018

    Ypsomed Diabetes Care – negotiations ongoing for distribution of mylife™ OmniPod® after June 2018  Ypsomed is interested in continuing distribution after June 2018. Negotiations with Insulet Corp. are on track.  Ypsomed is the best partner for Insulet in Europe. Ypsomed has excellent knowledge of

  25. Slide 25: Good strategic starting position in the insulin pump business

    Ypsomed Diabetes Care – Good strategic starting position in the insulin pump business  Ypsomed is currently active in two of three insulin pump segments: with the mylife™ YpsoPump® for conventional pumps and with the mylife™ OmniPod® for tubing free pumps.  In markets where Ypsomed sells the mylif

  26. Slide 26: Good strategic starting position in the insulin pump business

    Ypsomed Diabetes Care – Good strategic starting position in the insulin pump business  Ypsomed is well represented in Europe today. The remaining, yet not covered markets, will be addressed in the coming three years.  Several countries in Europe still have development potential in terms of insulin

  27. Slide 27: Good strategic starting position in the insulin pump business

    Ypsomed Diabetes Care – Good strategic starting position in the insulin pump business  Medtronic is the undisputed number 1 worldwide.  Some competitors have stopped focussing on the insulin pump business. This creates additional growth opportunities for Ypsomed.  Ypsomed is the fastest growing c

  28. Slide 28: Summary of the strategic starting position

    Ypsomed Diabetes Care – Summary of the strategic starting position  The operational cooperation with Insulet is good with low complaint rates and reliable product supplies.  Contract negotiations for continuing distribution of the mylife™ OmniPod® are on track. Ypsomed is interested in distributin

  29. Slide 29: Strategic starting position and our reaction

    Ypsomed Diabetes Care – Strategic starting position and our reaction  Ypsomed sees opportunities and continues to invest in this business segment.  After Czechia and Australia in 2016/17, additional new subsidiaries will follow in 2017/18: Poland, Spain, Belgium and New Zealand. In the former Yugo

  30. Slide 30: Delivery Systems

    Ypsomed Delivery Systems 30 | Ypsomed Holding AG | Presentation financial figures 2016/17

  31. Slide 31: Delivery Systems – Growth in sales through project revenues and first UnoPen deliveries

    Ypsomed Delivery Systems – Growth in sales through project revenues and first UnoPen™ deliveries 31 | Ypsomed Holding AG | Presentation financial figures 2016/17

  32. Slide 32: Delivery Systems – Average growth rate around 11%

    Ypsomed Delivery Systems – Average growth rate around 11% 32 | Ypsomed Holding AG | Presentation financial figures 2016/17

  33. Slide 33: Newly launched injection systems in the financial year 2016/17

    Ypsomed Delivery Systems – Newly launched injection systems in the financial year 2016/17 33 | Ypsomed Holding AG | Presentation financial figures 2016/17

  34. Slide 34: Market trend #1: Diabetes is a global pandemic

    Ypsomed Delivery Systems – Market trend #1 Diabetes is a global pandemic Source: IDF Diabetes Atlas, 7. edition 2015, WHO 2015. 34 | Ypsomed Holding AG | Presentation financial figures 2016/17

  35. Slide 35: Market trend #2: Patent cliff creates opportunities

    Ypsomed Delivery Systems – Market trend #2 Patent cliff creates opportunities Pen Autoinjector 35 | Ypsomed Holding AG | Presentation financial figures 2016/17

  36. Slide 36: Market trend #3: New drugs need to be injected

    Ypsomed Delivery Systems – Market trend #3 New drugs need to be injected 36 | Ypsomed Holding AG | Presentation financial figures 2016/17

  37. Slide 37: Diverse potentials for injection systems

    Ypsomed Delivery Systems – Diverse potentials for injection systems 37 | Ypsomed Holding AG | Presentation financial figures 2016/17

  38. Slide 38: Diverse potentials for injection systems

    Ypsomed Delivery Systems – Diverse potentials for injection systems 38 | Ypsomed Holding AG | Presentation financial figures 2016/17

  39. Slide 39: Diverse potentials for injection systems

    Ypsomed Delivery Systems – Diverse potentials for injection systems 39 | Ypsomed Holding AG | Presentation financial figures 2016/17

  40. Slide 40: Excellent strategic starting position in the pharmaceutical customer business

    Ypsomed Delivery Systems – Excellent strategic starting position in the pharmaceutical customer business  The three growth drivers – Diabetes pandemic, biosimilars and new drugs requiring parenteral administration – were assessed correctly and the platform strategy is paying dividends.  New busine

  41. Slide 41: Record pipeline with enormous potential for the future

    Ypsomed Delivery Systems – Record pipeline with enormous potential for the future 41 | Ypsomed Holding AG | Presentation financial figures 2016/17

  42. Slide 42: Projects will convert to commercial pen deliveries mid-term

    Ypsomed Delivery Systems – Projects will convert to commercial pen deliveries mid-term 43 | Ypsomed Holding AG | Presentation financial figures 2016/17

  43. Slide 43: Further development of our platforms

    Ypsomed Delivery Systems – Further development of our platforms 44 | Ypsomed Holding AG | Presentation financial figures 2016/17

  44. Slide 44: Further development of our platforms

    Ypsomed Delivery Systems – Further development of our platforms 45 | Ypsomed Holding AG | Presentation financial figures 2016/17

  45. Slide 45: Agenda

    Agenda 1. Introduction 2. Operative business 3. Finances 4. Outlook 5. Questions and answers 46 | Ypsomed Holding AG | Presentation financial figures 2016/17

  46. Slide 46: Profitability at EBIT level increased by over 24%

    Profitability at EBIT level increased by over 24% 47 | Ypsomed Holding AG | Presentation financial figures 2016/17

  47. Slide 47: Net profit increased by over 29%

    Net profit increased by over 29% 48 | Ypsomed Holding AG | Presentation financial figures 2016/17

  48. Slide 48: Cash balance increases operational flexibility

    Cash balance increases operational flexibility 49 | Ypsomed Holding AG | Presentation financial figures 2016/17

  49. Slide 49: External financing reduced further

    External financing reduced further 50 | Ypsomed Holding AG | Presentation financial figures 2016/17

  50. Slide 50: Investments above previous year

    Investments above previous year 51 | Ypsomed Holding AG | Presentation financial figures 2016/17

  51. Slide 51: Agenda

    Agenda 1. Introduction 2. Operative business 3. Finances 4. Outlook 5. Questions and answers 52 | Ypsomed Holding AG | Presentation financial figures 2016/17

  52. Slide 52: Outlook – financial year 2017/18

    Outlook – financial year 2017/18  YDC: Dynamic, competitive situation on the insulin pump market. We will invest more heavily into market penetration, geographic expansion and the further development of products.  YDS: Project business at an all-time high. The duration of clinical studies and appr

  53. Slide 53: Outlook – financial year 2017/18

    Outlook – financial year 2017/18  After the successful financial year 2016/17, we again expect to grow by approximately 15 % in the financial year 2017/18 at the turnover level.  At the EBIT level we are planning for the same or a slightly higher result as in the past year. 54 | Ypsomed Holding AG

  54. Slide 54: Outlook – Important dates

    Outlook – Important dates  General Assembly of Shareholders in Burgdorf 28. June 2017  Presentation of semi-annual figures 2017/18 in Zurich 9. November 2017 55 | Ypsomed Holding AG | Presentation financial figures 2016/17

  55. Slide 55: Agenda

    Agenda 1. Introduction 2. Operative business 3. Finances 4. Outlook 5. Questions and answers 56 | Ypsomed Holding AG | Presentation financial figures 2016/17

  56. Slide 56: Questions and answers

    _ Questions and answers

Ypsomed Holding — FY2016/17 Earnings Presentation on 6ix